Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users

AIDS Research and Human Retroviruses

Volumn 26, Issue 8, 2010, Pages 855-859

  Childs, Kathryn E ^a   Fishman, Sarah L ^a   Constable, Catherine ^a   Gutierrez, Julio A ^a   Wyatt, Christina M ^a   Dieterich, Douglas T ^a   Mullen, Michael P ^a   Branch, Andrea D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CREATININE; EMTRICITABINE; PARATHYROID HORMONE; TENOFOVIR; VITAMIN D; 25-HYDROXYVITAMIN D; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RISK FACTOR; VIRUS LOAD; VITAMIN D DEFICIENCY; VITAMIN INTAKE; ANALOGS AND DERIVATIVES; BLOOD; BONE DENSITY; COMPLICATION; CROSS-SECTIONAL STUDY; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED;

ADENINE; ADULT; ANTI-HIV AGENTS; BONE DENSITY; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHONIC ACIDS; VITAMIN D; VITAMIN D DEFICIENCY; ORGANOPHOSPHONATES;

EID: 77955620030     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0308     Document Type: Article

References (16)

1. Garcia Aparicio AM, Munoz Fernandez S, Gonzalez J, Arribas JR, Pena JM, Vazquez JJ, et al.: Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol 2006;25(4):537-539.
2. Triant VA, Brown TT, Lee H, and Grinspoon SK: Fracture prevalence among human immunodeficiency virus (HIV)- infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008;93(9):3499-3504.
3. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004;14;292(2):191-201.
4. Gilead: Viread (tenofovir disoproxil fumarate) package insert. [homepage on the Internet]. Gilead Sciences November 08. Available from http://www.gilead.com/pdf/viread-pi.pdf.
5. Jacobson DL, Spiegelman D, Knox TK, and Wilson IB: Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008;49(3):298-308.
6. Holick MF: Vitamin D deficiency. N Engl J Med 2007; 357(3):266-281.
7. Van Den Bout-Van Den Beukel, CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al.: Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: Effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008;24(11):1375-1382.
8. Rodriguez M, Daniels B, Gunawardene S, and Robbins GK: High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses 2009;25(1):9-14.
9. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, et al.: Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 2006;70(2):345-350.
10. National Kidney Foundation: KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease, 2003.
11. Essig M, Duval X, Kaied FA, Iordache L, Gervais A, Longuet P, et al.: Is phosphatemia the best tool to monitor renal tenofovir toxicity? J Acquir Immune Defic Syndr 2007;46(2): 256-258.
12. Taylor EN, Curhan GC, and Forman JP: Parathyroid hormone and the risk of incident hypertension. J Hypertens 2008;26(7):1390-1394.
13. Sahota O, Mundey MK, San P, Godber IM, Lawson N, and Hosking DJ: The relationship between vitamin D and parathyroid hormone: Calcium homeostasis, bone turnover, and bone mineral density in postmenopausal women with established osteoporosis. Bone 2004;35(1):312-319.
14. Von Borstel Smith M, Crofoot K, Rodriguez-Proteau R, and Filtz TM: Effects of phenytoin and carbamazepine on calcium transport in caco-2 cells. Toxicol In Vitro 2007;21(5): 855-862.
15. Solis-Herruzo JA, Castellano G, Fernandez I, Munoz R, and Hawkins F: Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 2000;33:812-817.
16. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, et al.: Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25- dihydroxyvitamin D(3): Implications for drug-induced osteomalacia. Mol Pharmacol 2006; 69:56-65.